Published: 2017-07-20

A study to assess the efficacy of metabolic control of diabetes in the development of neuropathy

MD. Mubasheer Ali, E. Ashok Kumar


Background: The metabolic syndrome is a deadly combination of hypertension, diabetes, heart disease, and dyslipidemia due to abdominal obesity. The causes this is both bad genes and bad environment. The objective of this study was to assess the efficacy of metabolic control of diabetes in the development of neuropathy.

Methods: The present hospital based cross sectional study was conducted at MNR Medical College and Hospital, Sangareddy. The study was undertaken between October 2012 to May 2014 both in inpatient and outpatient department. Diabetic patients seeking consultation for the symptoms suggestive of neuropathy were screened and labeled as suffering from diabetic neuropathy based on the inclusion and exclusion criteria.

Results: Diabetic neuropathy was common in the age group of 56 to 65 years in both male and female (33.3%). Average duration of diabetes was 8.7 years. Overall the rate of irregularity was much more (78%). Maximum (78%) patients reported presence of sensory symptoms. Diminision or loss of both ankle jerks was present in all 60 cases while 28 patients showed sluggish or absent knee jerks in total 60 patients. Maximum patients (60%) had distal symmetrical neuropathy.

Conclusions: Longstanding diabetes and poor glycaemic control are particularly associated with an increased risk of neuropathy in diabetes mellitus.


Diabetes, Efficacy, Metabolic control

Full Text:



Shashank JR. Technical monogram, Diabetic neuropathy. Mumbai Sam and Span Asian Health Care; 2003.

Zimmet PZ, McCarty DJ, de Courten MP. The global epidemiology of non-insulin dependent diabetes mellitus and the metabolic syndrome. J Diabetes Complicate. 1997;11:60-8.

Diabetes control and complications Trial. Research group. The effect of intensive treatment of diabetes on the development and progression of long term complication in insulin-dependent diabetes mellitus. New Eng J Med. 1993;329:977-86.

Diabetes control and complication trial research group. The effect of intensive diabetes, Therapy on the development and progression of Neuropathy. Ann Intern Med. 1996;125:561-8.

UK. Prospective diabetes study group intensive blood-glucose control with sulphonylureas or Insulin compared with conventional treatment and risk of complication in patient with types II diabetes. (UKPDS. 33) Lancet. 1998;352:837-53.

Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Bmj. 2000;321(7258):405-12.

Sheshiah HV. Monitoring the control of diabetes. Diabetes mellitus. 1989:104-110.

Pirart J. Diabetic neuropathy: A metabolic or vascular disease. Diabetes. 1965;14:1.

Holman RR, Turner R. Diabetes. The quest for normoglycemia. Lancet. 1976;1:469.

Service FJ, Daube JR, O’Brien PC et al. Effect of blood glucose control on peripheral nerve function in diabetic patients. Mayo Clin Proc. 1983;58:283-9.

Pirart J. Diabetic neuropathy: A metabolic or vascular disease. Diabetes. 1965;14:1.

Tesfaye S, Stevens LK, Stephenson JM, Fuller JH, Plater M, Ionescu-Tirgoviste C, et al. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. Diabetologia. 1996;39(11):1377-84.

Garland H. Diabetic amyotrophy. Br Med J. 1955;2:1287.

Keen H, Payan J, Allawi J, Walker J, Jamal GA, Weir AI, et al. Treatment of diabetic neuropathy with γ-linolenic acid. Diabetes Care. 1993;16(1):8-15.

Kurezyn AD. Bells Palsy and Diabetes Mellitus. Lancet. 1971;1:108.